Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 287

1.

Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression.

Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ, Kim DK.

JAMA. 2006 Oct 4;296(13):1609-18.

PMID:
17018806
2.

Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response.

Min W, Li T, Ma X, Li Z, Yu T, Gao D, Zhang B, Yun Y, Sun X.

Psychopharmacology (Berl). 2009 Aug;205(3):409-17. doi: 10.1007/s00213-009-1550-3. Epub 2009 May 26.

PMID:
19468717
3.

Serotonin transporter genotype and function in relation to antidepressant response in Koreans.

Myung W, Lim SW, Kim S, Kim H, Chung JW, Seo MY, Kim JW, Carroll BJ, Kim DK.

Psychopharmacology (Berl). 2013 Jan;225(2):283-90. doi: 10.1007/s00213-012-2813-y. Epub 2012 Aug 12.

PMID:
22885912
4.

Norepinephrine and serotonin transporter genes: impact on treatment response in depression.

Baffa A, Hohoff C, Baune BT, Müller-Tidow C, Tidow N, Freitag C, Zwanzger P, Deckert J, Arolt V, Domschke K.

Neuropsychobiology. 2010;62(2):121-31. doi: 10.1159/000317285. Epub 2010 Jun 30.

5.

Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life.

Seripa D, Pilotto A, Paroni G, Fontana A, D'Onofrio G, Gravina C, Urbano M, Cascavilla L, Paris F, Panza F, Padovani A, Pilotto A.

J Psychopharmacol. 2015 May;29(5):623-33. doi: 10.1177/0269881115578159. Epub 2015 Mar 31.

PMID:
25827644
6.

SERT and NET polymorphisms, temperament and antidepressant response.

Andre K, Kampman O, Illi A, Viikki M, Setälä-Soikkeli E, Mononen N, Lehtimäki T, Haraldsson S, Koivisto PA, Leinonen E.

Nord J Psychiatry. 2015;69(7):531-8. doi: 10.3109/08039488.2015.1012554. Epub 2015 Mar 5.

PMID:
25739526
7.

[Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods].

Higuchi H.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Apr;30(2):71-6. Review. Japanese.

PMID:
20491280
8.

Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder.

Won ES, Chang HS, Lee HY, Ham BJ, Lee MS.

Neuropsychobiology. 2012;66(4):221-9. doi: 10.1159/000341876. Epub 2012 Oct 20.

PMID:
23095326
10.

The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients.

Smits KM, Smits LJ, Peeters FP, Schouten JS, Janssen RG, Smeets HJ, van Os J, Prins MH.

Psychiatr Genet. 2008 Aug;18(4):184-90. doi: 10.1097/YPG.0b013e3283050aca.

PMID:
18628680
11.

Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients.

Manoharan A, Shewade DG, Rajkumar RP, Adithan S.

Eur J Clin Pharmacol. 2016 Oct;72(10):1215-1220. doi: 10.1007/s00228-016-2099-9. Epub 2016 Jul 20.

PMID:
27439447
12.

The serotonin transporter promoter polymorphism (5-HTTLPR) affects the relation between antidepressant serum concentrations and effectiveness in major depression.

Dreimüller N, Tadić A, Dragicevic A, Boland K, Bondy B, Lieb K, Laux G, Maier W, Müller MJ, Rao ML, Rietschel M, Röschke J, Zill P, Hiemke C.

Pharmacopsychiatry. 2012 May;45(3):108-13. doi: 10.1055/s-0031-1291347. Epub 2011 Nov 15.

PMID:
22086748
13.

Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.

Hu XZ, Rush AJ, Charney D, Wilson AF, Sorant AJ, Papanicolaou GJ, Fava M, Trivedi MH, Wisniewski SR, Laje G, Paddock S, McMahon FJ, Manji H, Lipsky RH.

Arch Gen Psychiatry. 2007 Jul;64(7):783-92.

PMID:
17606812
14.

Fluoxetine response in impulsive-aggressive behavior and serotonin transporter polymorphism in personality disorder.

Silva H, Iturra P, Solari A, Villarroel J, Jerez S, Jiménez M, Galleguillos F, Bustamante ML.

Psychiatr Genet. 2010 Feb;20(1):25-30. doi: 10.1097/YPG.0b013e328335125d.

PMID:
20010449
16.

Potential involvement of NET polymorphism in serotonin/norepinephrine reuptake inhibitor response in panic disorder.

Park HJ, Kim SK, Kang WS, Kim YJ, Cho AR, Park JK.

Nord J Psychiatry. 2016;70(4):314-7. doi: 10.3109/08039488.2015.1089321. Epub 2015 Oct 27.

PMID:
26508020
17.

Serotonin transporter gene polymorphism and antidepressant response.

Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, Carroll BJ.

Neuroreport. 2000 Jan 17;11(1):215-9.

PMID:
10683861
18.

Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder.

Hong CJ, Chen TJ, Yu YW, Tsai SJ.

Pharmacogenomics J. 2006 Jan-Feb;6(1):27-33.

PMID:
16302021
19.

Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms.

Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, Naito S, Shimizu T, Itoh K, Inoue K, Suzuki T, Nemeroff CB.

Am J Psychiatry. 2004 Sep;161(9):1575-80.

PMID:
15337646
20.

Escitalopram efficacy in depression: a cross-ethnicity examination of the serotonin transporter promoter polymorphism.

Bousman CA, Sarris J, Won ES, Chang HS, Singh A, Lee HY, Ham BJ, Tan CH, Lee MS, Ng CH.

J Clin Psychopharmacol. 2014 Oct;34(5):645-8. doi: 10.1097/JCP.0000000000000165.

PMID:
24943391

Supplemental Content

Support Center